●The mouse genome.Nature 5 December (2002). Seminal series of papers that describe the sequence and analysis of one of drug discovery's most important preclinical models.

●Reversing cocaine addiction. William A. Carlezon Nature Medicine January (2002) This News and Views discusses primary data in Nature showing that upregulation of certain receptors in the brain can reduce cocaine-seeking behaviour.

●Yin outwits yang at the IgE locus. Nancy Maizels Nature Immunology January (2002)

●Validating survivin as a cancer therapeutic target. Dario C. Altieri Nature Reviews Cancer January (2002) The identification and validation of translational targets for apoptosis-based cancer therapy has posed a great challenge. Survivin is an attractive candidate for cancer therapy, so what is its potential applicability in the clinic?

●Is proteomics heading in the wrong direction? Lukas A. Huber Nature Reviews Molecular Cell Biology January (2002)

●Unfolding the role of protein misfolding in neurodegenerative diseases. Claudio Soto Nature Reviews Neuroscience January (2002)

●Protozomics – Trypanosomatid genetics comes of age: Stephen M. Beverley Nature Reviews Genetics January (2002)

●Novel interferons. Jan Wilcek Nature Immunology January (2002)

●Whole virus-loaded dendritic-cell vaccine for AIDS. Bruce Walker Nature Medicine January (2002)

●Targeting Ras signalling pathways in cancer therapy. Julian Downward Nature Reviews Cancer January (2002) Rational therapies that target the Ras pathways might inhibit tumour growth, survival and spread. Several of these novel therapeutic agents are showing promise in the clinic and many more are under development.